S&P 5007,722.60▲0.6% Nasdaq26,477.81▲1.2% Dow52,377.57▲0.0% Russell 2K2,818.87▲1.2% 10-Yr4.99%+1bp VIX17.52−0.87 WTI$100.46▼1.3% Gold$4,079.60▲1.0% EUR/USD1.113▼0.4% BTC$80,107▼1.4% Nikkei64,131▲3.1%
At close · Wed, Oct 28, 2026
Daily Market Updates.

US Markets

Home›US Markets›Equities›Merck tops quarterly estimates, hikes profit outlook a…

Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Reported · Written up by our desk · Equities

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.

← Newer storyEuro: Cautious ECB outlook weighs – Commerzbank

More like this

US MarketsEli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
US MarketsPoundland's future hangs in the balance as chain edges towards collapse
US MarketsPutin praises Elon Musk as a ‘genius’ as Russia develops Starlink alternative
US MarketsAlphabet earnings miss reflects first real sign that AI is taking a bite out of search
US MarketsHong Kong Leader Apologizes for Deadly Apartment Building Fire

Sources

CNBC MarketsMerck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength
CNBC EarningsMerck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.